Multi-Drug Resistant Tuberculosis – International Resources for Canadian Public Health Personnel

COMMENTARY: Yoav Keynan, MD and NCCID’s Scientific Lead COMMENT According to the WHO 2017 report, in 2016 globally, there were 600,000 new cases of tuberculosis with resistance to rifampicin, the most effective first-line drug, of which 490,000 cases had multidrug-resistant TB (MDR-TB), defined as resistance to rifampicin and isoniazid. Almost half (47%) of these cases…